Abstract
Introduction
Osteoporosis continues to be an attractive therapy area for large
pharmaceutical companies due to its high prevalence rate and unmet need.
Globally, sales for osteoporosis drugs grew 7.0% year-on-year from 2004 to
$9.6 billion in 2008 driven by strong performance of the bisphosphonate class.
Scope of this research
- Patient potential analysis across the seven major markets and BRIC nations
(Brazil, Russia, India, and China).
- Analysis of global osteoporosis prescriptions from 20042008, split by
geographical region, drug class, molecule, and brand.
- In depth profiles of key current osteoporosis brands including SWOT
analyses and country-specific sales forecasts to 2018.
- R&D pipeline analysis with detailed profiles and forecasts of key agents,
including Amgen' s denosumab and new selective estrogen receptor modulators.
Research and analysis highlights
The osteoporosis seven major market value was $7.1 billion in 2008, 76.4% of
the global market. Although between 2007 and 2008 the market declined due to
generic penetration of the market leading brand Fosamax (alendronate, Merck &
Co), the launch of new pipeline drugs will result in a significant market
growth.
The launch of four pipeline selective estrogen receptor modulators (SERMs)
between 2009 and 2012 will boost class sales across the seven major markets.
However, the challenge for marketing companies is to convince prescribers in
the EU, where uptake has historically been low, of the effect of SERMs in the
wider patient group.
The largest growth driver of the osteoporosis market over the forecast period
is expected to be Amgen' s denosumab, potentially the first monoclonal antibody
to market. However, success will rely on a good long-term safety profile and
price competitiveness, which are relative unknowns at this stage.
Key reasons to purchase this research
- Understand current and future osteoporosis drug market dynamics
- Gain insight into the unmet needs of current osteoporosis treatment and to
what extent pipeline drugs will address these issues
- Evaluate the sales forecasts of marketed, generic, and key pipeline drugs
to 2018 in the US, Japan, France, Germany, Italy, Spain, and the UK
| 
View Cart
